Headquartered in Malvern, Pennsylvania, Encore Dermatology is a privately held fully integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.
Encore has a wide range of medical dermatology products, treating a number of topical disease states such as acne and atopic dermatitis. Encore Dermatology is rapidly expanding through acquisitions, in- licensing and co-marketing opportunities.
Encore has a wide range of medical dermatology products, treating a number of topical disease states such as acne and atopic dermatitis. Encore Dermatology is rapidly expanding through acquisitions, in- licensing and co-marketing opportunities.
Location: United States, Pennsylvania, Malvern
Total raised: $20M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Park Lane ... | plvc.com/ |
| - | EW Healthc... | ewhealthca... |
| - | Longitude ... | longitudec... |
| - | Horizon Te... | horizontec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.04.2019 | - | $20M | - |
Mentions in press and media 5
| Date | Title | Description |
| 09.04.2019 | Encore Dermatology Receives $20M Venture Loan Facility from Horizon Technology Finance | Encore Dermatology, Inc., a Malvern, Pennsylvania-based dermatologically-focused specialty pharmaceutical company, received a $20m venture loan facility from Horizon Technology Finance Corporation (NASDAQ: HRZN). $15m out of the total finan... |
| 08.04.2019 | Encore Dermatology Secures $20M from Horizon | Horizon Technology Finance Corporation (NASDAQ: HRZN), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and se... |
| 02.04.2019 | Encore Dermatology Inc. Acquires SERNIVO®, TRIANEX® and PROMISEB®. | Apr 02 2019 MALVERN, Pennsylvania—Encore Dermatology Inc. announced today that it has acquired rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05%, as well as rights to market and distribute TRIANEX® 0.05% (Triamcinolone Acetonid... |
| 15.06.2016 | PE firm 1315 Capital raises $200M fund to invest in health tech, life sciences | What specific health technology trends spark your interest? We believe there is a significant opportunity in the smaller end of healthcare growth equity where Michael Koby and I have spent the vast majority of our investing careers. Massive... |
| - | PE firm 1315 Capital raises $200M fund to invest in health tech, life sciences | Philadelphia private equity firm 1315 Capital has raised $200 million for its first fund targeting health tech, life sciences and healthcare services investments. Its investors include endowments, foundations, state and corporate pension fu... |